<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01126749</url>
  </required_header>
  <id_info>
    <org_study_id>E7389-702</org_study_id>
    <secondary_id>2009-015915-42</secondary_id>
    <nct_id>NCT01126749</nct_id>
  </id_info>
  <brief_title>Eribulin Mesylate Administered in Combination With Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Cisplatin Alone as First-Line Therapy for Locally Advanced or Metastatic Bladder Cancer</brief_title>
  <official_title>An Open-Label, Multicenter, Randomized Phase Ib/II Study of Eribulin Mesylate Administered in Combination With Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Cisplatin Alone as First-Line Therapy for Locally Advanced or Metastatic Bladder Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eisai Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>PharmaBio Development Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Eisai Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether Patients with Locally Advanced or&#xD;
      Metastatic Bladder Cancer who receive Eribulin Mesylate Administered in Combination with&#xD;
      Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Cisplatin Alone as First-Line Therapy is&#xD;
      safety and tolerable when administered to patients with locally advanced or metastatic&#xD;
      bladder cancer and to gain preliminary data on whether patients may benefit from this&#xD;
      combination.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This open-label, multicenter, randomized study will consist of 2 phases:&#xD;
&#xD;
        -  Phase Ib: a safety run-in period with 3 ascending doses of eribulin;&#xD;
&#xD;
        -  Phase II: a randomized 2-arm design. Phase Ib Patients will be recruited into cohorts,&#xD;
           with a minimum of 3 and a maximum of 6 patients per cohort. All patients will receive&#xD;
           the same dose of gemcitabine (1000 mg/m2 on Days 1 and 8 of a 21-day cycle) and&#xD;
           cisplatin (70 mg/m2 on Day 1) in combination with eribulin (administered on Days 1 and 8&#xD;
           of the cycle). All patients in a cohort will receive the same dose level of eribulin.&#xD;
&#xD;
      The dose level of eribulin will be escalated for additional cohorts unless greater than 2&#xD;
      dose limiting toxicities (DLTs) are reported at the lower dose level(s) prior to enrollment&#xD;
      of the next dose level. If one DLT occurs at any dose level, the cohort will be expanded to&#xD;
      include up to a maximum of 6 patients.&#xD;
&#xD;
      A Dose Escalation Committee will determine when no further dose escalation is appropriate and&#xD;
      whether the MTD will be defined as a preceding dose or an intermediate dose.&#xD;
&#xD;
      Phase II Patients will be randomized in a 1:1 ratio to receive either eribulin in combination&#xD;
      with gemcitabine plus cisplatin (Arm 1) or gemcitabine plus cisplatin alone (Arm 2). The&#xD;
      eribulin dose will be 1.0 mg/m2 administered on Days 1 and 8 of each 21-day treatment cycle,&#xD;
      the recommended Phase II dose for eribulin when administered in combination gemcitabine plus&#xD;
      cisplatin, as determined in the Phase Ib portion of the study.&#xD;
&#xD;
      Allocation of patients will be stratified based on metastatic disease status (patients with&#xD;
      visceral metastases versus patients with non-visceral metastases). This stratified&#xD;
      randomization will be centrally allocated across all centers via an Interactive Voice&#xD;
      Activated Response System (IVRS).&#xD;
&#xD;
      For both the Phase Ib and Phase II portions, 1 cycle of therapy will last 21 days, with a&#xD;
      maximum number of 6 gemcitabine plus cisplatin cycles. Radiologic examinations including a&#xD;
      computed tomography (CT) scan of the chest, abdomen, and pelvis as appropriate (and CT or&#xD;
      magnetic resonance imaging [MRI] scan as appropriate), will be performed during Screening and&#xD;
      after every 6 weeks while on therapy. In the case of dose delays, scans should be performed&#xD;
      according to the original Cycle 1 Day 1 schedule (ie, scans should not be delayed).&#xD;
      Radiographic assessments should be repeated at withdrawal if the last assessment was obtained&#xD;
      greater than 3 weeks from withdrawal of therapy. Patients will be followed until death&#xD;
      following completion of therapy. Scans will be required every 2 months until documentation of&#xD;
      PD or the start of a next line of therapy, whichever occurs first. In patients experiencing&#xD;
      PD, follow-up will be for survival only and radiographic scans are not required.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 2010</start_date>
  <completion_date type="Actual">July 20, 2016</completion_date>
  <primary_completion_date type="Actual">May 9, 2015</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety parameters</measure>
    <time_frame>[Time Frame: AEs and conmeds - until study termination; lab tests Day 1 and every 21 days until study termination; ECGs - Day 1 and 21 days after therapy ended</time_frame>
    <description>Safety parameters: adverse events (AEs); vital signs; ECOG PS; clinical laboratory evaluations; physical examinations; and 12 lead electrocardiograms (ECGs).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy Measures</measure>
    <time_frame>Until disease progression or death</time_frame>
    <description>Progression-free survival (PFS)l [Time Frame: Until disease progression or death]&#xD;
Time to Progression(TTP): Time Frame: Until disease progression or Death]&#xD;
Overall survival (OS); [Time Frame: until death]&#xD;
Overall Response Rate (ORR), the number and percentage of patients with Complete Response (CR); Partial Response (PR), Stable Disease (SD) and Progressive Disease (PD) [Time frame: Until completion of study or every 2 months during follow-up for 1 year]</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">92</enrollment>
  <condition>Bladder Cancer</condition>
  <arm_group>
    <arm_group_label>E7389 in combination with gemcitabine plus cisplatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>gemcitabine plus cisplatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gemcitabine plus cisplatin</intervention_name>
    <description>Eribulin Mesylate plus Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Cisplatin</description>
    <arm_group_label>E7389 in combination with gemcitabine plus cisplatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>E7389 in combination with gemcitabine plus cisplatin</intervention_name>
    <description>Eribulin Mesylate plus Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Cisplatin</description>
    <arm_group_label>gemcitabine plus cisplatin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        Patients may be entered in the study only if they meet all of the following criteria:&#xD;
&#xD;
          1. Male or female patient greater than 18 years of age;&#xD;
&#xD;
          2. Histologically or cytologically confirmed, locally advanced Stage 4 (eg, T4b) or&#xD;
             metastatic transitional cell cancer of the bladder; including other transitional cell&#xD;
             cancers of the urothelium (prostate, urethra, ureter, and renal pelvis)&#xD;
&#xD;
          3. Not previously treated with systemic chemotherapy for metastatic bladder cancer (one&#xD;
             regimen of adjuvant or neoadjuvant chemotherapy is permitted). Patients must have a&#xD;
             disease-free interval of 6 months after adjuvant therapy;&#xD;
&#xD;
          4. At least 1 site of measurable disease by the Response Evaluation Criteria in Solid&#xD;
             Tumors version 1.1 (RECIST version 1.1) guidelines;&#xD;
&#xD;
          5. Life expectancy of greater than or equal to 3 months;&#xD;
&#xD;
          6. Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0 or 1;&#xD;
&#xD;
          7. Patients must have active bowel function defined as at least 3 bowel movements per&#xD;
             week according to subject history and must be willing to maintain a diary of bowel&#xD;
             function prior to dosing and continuing through completion of study treatment.&#xD;
             Laxatives may be used to maintain adequate bowel function;&#xD;
&#xD;
          8. Patients must have adequate renal function as evidenced by calculated creatinine&#xD;
             clearance greater than or equal to 55 mL/min per the Cockcroft and Gault formula;&#xD;
&#xD;
          9. Patients must have adequate bone marrow function as evidenced by absolute neutrophil&#xD;
             count (ANC) greater than or equal to 1.5 x 10^9/L, hemoglobin greater than or equal to&#xD;
             10.0 g/dL (a hemoglobin less than 10.0 g/dL at Screening is acceptable if it is&#xD;
             corrected to greater than or equal to 10.0 g/dL by growth factor or transfusion prior&#xD;
             to first dose), and platelet count greater than or equal to 100 x 10^9/L;&#xD;
&#xD;
         10. Patients must have adequate liver function as evidenced by bilirubin less than or&#xD;
             equal to 1.5 times the upper limit of the normal range (ULN), and alkaline&#xD;
             phosphatase, alanine aminotransferase (ALT), and aspartate aminotransferase (AST) less&#xD;
             than or equal to 3 x ULN (in the case of liver metastases, less than or equal to 5 x&#xD;
             ULN). If there are bone metastases, liver-specific alkaline phosphatase may be&#xD;
             separated from the total and used to assess liver function instead of total alkaline&#xD;
             phosphatase;&#xD;
&#xD;
         11. Male or female patients of child-producing potential must agree to use double barrier&#xD;
             contraception, oral contraceptives, or avoidance of pregnancy measures during the&#xD;
             study and for 90 days after the last day of treatment;&#xD;
&#xD;
         12. Females of childbearing potential must have a negative serum pregnancy test at&#xD;
             screening;&#xD;
&#xD;
         13. Females may not be breastfeeding;&#xD;
&#xD;
         14. Ability to understand and willingness to sign a written informed consent.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
        Patients will not be entered in the study for any of the following reasons:&#xD;
&#xD;
          1. Prior treatment with epothilone, ixabepilone, patupilone, vinflunine, halichondrin B,&#xD;
             and/or halichondrin B chemical derivatives;&#xD;
&#xD;
          2. History of other malignancies except: (1) adequately treated basal or squamous cell&#xD;
             carcinoma of the skin; (2) curatively treated, a) in situ carcinoma of the uterine&#xD;
             cervix, or b) prostate cancer, or c) superficial bladder cancer; or (3) other&#xD;
             curatively treated solid tumor with no evidence of disease for greater than or equal&#xD;
             to 3 years;&#xD;
&#xD;
          3. Presence of brain metastases, unless the patient has received adequate treatment at&#xD;
             least 4 weeks prior to randomization, and is stable, asymptomatic, and off steroids&#xD;
             for at least 4 weeks prior to randomization;&#xD;
&#xD;
          4. Received an investigational agent, chemotherapy, biological therapy, hormonal therapy,&#xD;
             targeted therapy, or radiotherapy within 30 days prior to commencing study treatment,&#xD;
             or have not recovered from all treatment-related toxicities to Common Toxicity&#xD;
             Criteria (CTC) Grade less than or equal to 1, except for alopecia;&#xD;
&#xD;
          5. Are currently receiving an investigational agent or any other systemic anticancer&#xD;
             treatment, including palliative radiotherapy;&#xD;
&#xD;
          6. Significant cardiovascular impairment (history of congestive heart failure New York&#xD;
             Heart Association [NYHA] Grade greater than 2, unstable angina or myocardial&#xD;
             infarction within the past 6 months, or serious cardiac arrhythmia);&#xD;
&#xD;
          7. Subjects with a high probability of Long QT Syndrome;&#xD;
&#xD;
          8. Patients with organ allografts requiring immunosuppression;&#xD;
&#xD;
          9. Known active infection with human immunodeficiency virus (HIV), hepatitis B, virus&#xD;
             (HBV) or hepatitis C; virus (HCV);&#xD;
&#xD;
         10. Hypersensitivity to halichondrin B and/or halichondrin B chemical derivative&#xD;
&#xD;
         11. Prior pelvic radiation;&#xD;
&#xD;
         12. History of known or suspected peritoneal carcinomatosis with risk of bleeding or&#xD;
             perforation, or intraluminal or serosal metastatic lesions with risk of bleeding or&#xD;
             perforation of any lesions;&#xD;
&#xD;
         13. History of abdominal adhesions, fistula, diverticulitis, gastrointestinal perforation,&#xD;
             intra-abdominal abscess, documented peptic ulcer disease (active gastroesophageal&#xD;
             reflux disease/dyspepsia are allowed), or other gastrointestinal conditions with&#xD;
             increased risk of perforation;&#xD;
&#xD;
         14. Common Terminology Criteria for Adverse Events, version 4.0 (CTCAE v.4.0) Grade&#xD;
             greater than or equal to 2 constipation;&#xD;
&#xD;
         15. CTCAE v.4.0 Grade greater than or equal to 2 peripheral neuropathy;&#xD;
&#xD;
         16. Have any medical condition that would interfere with the conduct of the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85715</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fort Myers</city>
        <state>Florida</state>
        <zip>33916</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <zip>33705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89169</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>East Orange</city>
        <state>New Jersey</state>
        <zip>7018</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>55904</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Webster</city>
        <state>Texas</state>
        <zip>77598</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Huntington</city>
        <state>Virginia</state>
        <zip>25704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Northfork</city>
        <state>West Virginia</state>
        <zip>23502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Aachen NW</city>
        <zip>52074</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Essen, NW</city>
        <zip>45136</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Goch, NW</city>
        <zip>47574</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hamburg, HH</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tuebingen, BW</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wiesbaden, HE</city>
        <zip>65191</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Maastricht</city>
        <zip>6229</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nieuwegein</city>
        <zip>3435</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nijmegen</city>
        <zip>6525</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Barcelona</city>
        <zip>8003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Barcelona</city>
        <zip>8025</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Elche- Alicante</city>
        <zip>3203</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Madrid</city>
        <zip>28050</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sabadell</city>
        <zip>8208</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dnipropetrovsk</city>
        <zip>49005</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dnipropetrovsk</city>
        <zip>49102</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Donetsk</city>
        <zip>83092</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kharkiv</city>
        <zip>61037</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kyiv</city>
        <zip>3022</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lviv</city>
        <zip>79031</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Leicester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Liverpool</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Manchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Southampton</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>Ukraine</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>France</country>
  </removed_countries>
  <verification_date>August 2017</verification_date>
  <study_first_submitted>May 17, 2010</study_first_submitted>
  <study_first_submitted_qc>May 19, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 20, 2010</study_first_posted>
  <last_update_submitted>August 25, 2017</last_update_submitted>
  <last_update_submitted_qc>August 25, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Locally Advanced or Metastatic Bladder Cancer, including other transitional cell cancers of the urothelium (prostate, urethra, ureter, and renal pelvis)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

